Department of Traditional Chinese Medicine, Wuhan Asia General Hospital, Wuhan, Hubei, China.
Medicine (Baltimore). 2021 Oct 29;100(43):e27646. doi: 10.1097/MD.0000000000027646.
From the perspective of evidence-based medicine, the efficacy and safety of combined therapy for marrow suppression after chemotherapy is still unclear. Given that there is no high-quality meta-analysis to incorporate existing evidence, the purpose of this protocol is to design a systematically review and meta-analysis of the level I evidence to ascertain the efficacy and safety of acupuncture combined with traditional Chinese medicine preparation for marrow suppression after chemotherapy.
The following databases will be searched electronically by keyword combination mode: 4 British literature databases including PubMed, EMBASE, Scopus, and Cochrane Library, and 4 Chinese literature databases, including Chinese national knowledge infrastructure, VIP, and Wan fang database. The randomized controlled trials on acupuncture plus traditional Chinese medicine preparation for marrow suppression after chemotherapy will be included. The primary outcome is the elevation of hemoglobin, platelets, leukocytes, and neutrophils. The other outcomes include clinical symptoms, quality of life, and absolute value of reticulocyte. Risk bias analysis of the studies will be performed independently by 2 reviewers using the Cochrane Risk of Bias Assessment Tool.
The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.
This protocol will provide a reliable theoretical basis for the following research.
从循证医学的角度来看,化疗后骨髓抑制的联合治疗的疗效和安全性仍不清楚。鉴于没有高质量的荟萃分析来整合现有证据,本方案旨在设计一项 I 级证据的系统评价和荟萃分析,以确定针刺联合中药制剂治疗化疗后骨髓抑制的疗效和安全性。
通过关键词组合模式对以下数据库进行电子检索:4 个英国文献数据库,包括 PubMed、EMBASE、Scopus 和 Cochrane Library,以及 4 个中文文献数据库,包括中国知网、维普和万方数据库。纳入针刺加中药制剂治疗化疗后骨髓抑制的随机对照试验。主要结局是血红蛋白、血小板、白细胞和中性粒细胞的升高。其他结局包括临床症状、生活质量和网织红细胞绝对值。使用 Cochrane 偏倚风险评估工具,由 2 名评审员独立对研究进行风险偏倚分析。
该综述将通过提供有说服力的证据和改善临床实践指导,为现有文献增添内容。
本方案将为以下研究提供可靠的理论依据。